Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN321 in Symptomatic Knee Osteoarthritis
2024-517920-21-00Phase 2Completed
- Sponsor
- Synartro
- Start
- Aug 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SYN321 in knee osteoarthritis (OA) (4 arms), sponsored by Synartro. Primary endpoint: Safety and tolerability of SYN321. Started Aug 2025; status: completed.
02
Drugs
SYN321
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-517920-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517920-21-00.